Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Operating Leases (2019 - 2025)

Historic Operating Leases for ImmunoTech (AIM) over the last 5 years, with Q3 2025 value amounting to $458000.0.

  • ImmunoTech's Operating Leases fell 3153.96% to $458000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $458000.0, marking a year-over-year decrease of 3153.96%. This contributed to the annual value of $634000.0 for FY2024, which is 2808.08% up from last year.
  • Per ImmunoTech's latest filing, its Operating Leases stood at $458000.0 for Q3 2025, which was down 3153.96% from $515000.0 recorded in Q2 2025.
  • Over the past 5 years, ImmunoTech's Operating Leases peaked at $669000.0 during Q3 2024, and registered a low of $338000.0 during Q1 2025.
  • In the last 3 years, ImmunoTech's Operating Leases had a median value of $526000.0 in 2024 and averaged $527400.0.
  • Per our database at Business Quant, ImmunoTech's Operating Leases surged by 2808.08% in 2024 and then tumbled by 3705.77% in 2025.
  • Quarter analysis of 3 years shows ImmunoTech's Operating Leases stood at $495000.0 in 2023, then increased by 28.08% to $634000.0 in 2024, then fell by 27.76% to $458000.0 in 2025.
  • Its Operating Leases stands at $458000.0 for Q3 2025, versus $515000.0 for Q2 2025 and $338000.0 for Q1 2025.